Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

The Spine, Liverpool

2025 BioInfect Conference

The agenda at BioInfect will focus on the issues surrounding the increasing threat of AMR and how it can be addressed.

Go to Top